drugset
Drugs / CD30+ CAR T-cells
last change 10 days ago re-read 9 days ago

CD30+ CAR T-cells

Cell therapy

Developed for
classic Hodgkin lymphoma
Investigated by
Memorial Sloan Kettering Cancer Center · New York Medical College · University of North Carolina

Trials 1

today NCT07575893 · Ph 1
202720282029203020312032
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT07575893 Oct 2026 → Dec 2031 expected classic Hodgkin lymphoma New York Medical College Not yet recruiting No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as CD30+ CAR T-cells ClinicalTrials.gov intervention name — accepted as the source's own label NCT07575893 ↗
Modality Cell therapy “autologous CD30 CAR T-cells” NCT07575893 ↗